Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (NASDAQ: BNTX) generates frequent news flow as a global next generation immunotherapy company focused on oncology, mRNA technologies and COVID-19 vaccines. Its updates often cover progress across a diversified oncology pipeline that includes mRNA cancer immunotherapies, next-generation immunomodulators, antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T cell therapies, as well as developments in its mRNA vaccine programs for infectious diseases.
Investors following BioNTech news can expect regular announcements on clinical trial milestones in major tumor types such as lung, breast, gynecologic, gastrointestinal and genitourinary cancers. Recent releases have highlighted late-stage data readouts and trial initiations for investigational agents like pumitamig (a PD-L1xVEGF-A bispecific antibody co-developed with Bristol Myers Squibb) and gotistobart (a CTLA-4–targeting Treg modulator), including Phase 2 and Phase 3 results in indications such as triple-negative breast cancer and squamous non-small cell lung cancer.
BioNTech’s news stream also includes corporate and financial updates, such as quarterly results, guidance changes, and details of its cash and investment position. The company reports on its COVID-19 vaccine franchise, including launches of variant-adapted vaccines for specific vaccination seasons, and comments on how vaccine market dynamics affect revenues.
Another recurring theme in BNTX news is strategic transactions and partnerships. BioNTech has announced an all-stock acquisition of CureVac N.V. to strengthen its position in mRNA design, delivery formulations and manufacturing, and regularly issues releases on its collaboration with partners including Bristol Myers Squibb, Duality Biologics, OncoC4, Pfizer and others.
This news page aggregates these developments in one place, allowing readers to track BioNTech’s clinical progress, partnership activity, financial disclosures and strategic updates over time.
BioNTech (NASDAQ:BNTX) and Pfizer have received a positive CHMP opinion for their LP.8.1-adapted COVID-19 vaccine in the European Union. The updated vaccine demonstrates improved immune response against dominant variants including XFG and NB.1.8.1 compared to 2024-2025 formulations.
Upon European Commission authorization, the vaccine will be available for individuals 6 months and older. The companies have already initiated manufacturing to ensure supply readiness for the upcoming fall/winter season, with doses ready to ship immediately following EC approval.
The recommendation is supported by comprehensive clinical, non-clinical, and real-world data, with over a billion doses administered globally demonstrating favorable safety and efficacy profiles.
BioNTech (NASDAQ: BNTX) has scheduled its second quarter 2025 financial results announcement and corporate update for August 4, 2025. The company will host a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day.
Investors and analysts can access the conference call via telephone by registering through a provided link, which will supply dial-in numbers and a PIN. The presentation slides and webcast will be accessible through the company's website, with a replay available for 30 days after the event.
BioNTech (NASDAQ: BNTX) announced that Chief Strategy Officer Ryan Richardson will step down from the Management Board effective September 30, 2025. Richardson, who joined in 2018 and served as CSO since January 2020, played a crucial role in the company's development, including raising over $1 billion in capital through Series B financing, IPO, and follow-on offerings.
During his tenure, Richardson led Global Strategy and Corporate Development functions, overseeing more than a dozen collaborations and acquisitions. He also managed Capital Markets and Investor Relations, expanding analyst coverage and strengthening BioNTech's global shareholder base. His responsibilities will be transitioned to other Management Board members to ensure a smooth handover.
BioNTech SE (Nasdaq: BNTX) reported Q1 2025 financial results with revenues of €182.8 million, primarily driven by COVID-19 vaccine collaboration. The company posted a net loss of €415.8 million and loss per share of €1.73. Despite losses, BioNTech maintains a strong financial position with €15.9 billion in cash and investments.
Key highlights include advancement in oncology pipeline, particularly BNT327 (PD-L1xVEGF-A bispecific antibody) and mRNA cancer immunotherapies. The company confirmed its 2025 revenue guidance of €1.7-2.2 billion and announced preparation for 2025/2026 variant-adapted COVID-19 vaccine.
BioNTech (NASDAQ: BNTX) has appointed Ramón Zapata-Gomez as its new Chief Financial Officer, effective July 1, 2025. Zapata will succeed Jens Holstein, who will retire as planned on June 30, 2025. Zapata joins from Novartis AG, where he served as CFO of their global biomedical research organization since 2022.
With over 25 years of experience in pharmaceutical and consumer goods industries, Zapata brings extensive expertise in finance, M&A, and digital transformations. His appointment aligns with BioNTech's strategy to become a multi-product oncology company. In his new role, Zapata will focus on optimizing financial infrastructure, performance in key markets, and driving cost-effective value generation as the company prepares for oncology product launches.
BioNTech (NASDAQ: BNTX) will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago (April 25-30, 2025). The presentations will feature:
1. BNT327: A next-generation bispecific antibody showing superior anti-tumor activity in preclinical studies when combined with antibody-drug conjugates (ADCs)
2. BNT116: Phase 1 clinical trial data in combination with cemiplimab for non-small cell lung cancer (NSCLC), demonstrating anti-tumor activity and manageable safety profile
3. BNT314/GEN1059: Preclinical data showing enhanced anti-tumor activity when combined with PD-1 inhibition
The company's oncology portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, with over 20 active Phase 2 and 3 trials. Multiple data readouts are expected in 2025 and 2026.